Get the Stockscreener App
1.78
2.01%
0.035
Dare Bioscience Inc stock is traded at $1.78, with a volume of 119.34K.
It is up +2.01% in the last 24 hours and down -1.66% over the past month.
Dare Bioscience Inc is a biopharmaceutical company committed to advancing products for women's health. The company identifies, develops, and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in clinical development namely, Ovaprene and Sildenafil Cream. It has one operating segment, women's health.
See More
Previous Close:
$1.745
Open:
$1.75
24h Volume:
119.34K
Relative Volume:
0.89
Market Cap:
$25.43M
Revenue:
-
Net Income/Loss:
$-30.16M
P/E Ratio:
-5.2353
EPS:
-0.34
Net Cash Flow:
$-39.49M
1W Performance:
-1.66%
1M Performance:
-1.66%
6M Performance:
-42.58%
1Y Performance:
-45.23%
1-Day Range:
$1.71
$1.80
1-Week Range:
$1.64
$1.8582
52-Week Range:
$1.61
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
Name
Dare Bioscience Inc
Sector
Industry
Phone
858-926-7655
Address
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
1.78 | 24.93M | 0 | -30.16M | -39.49M | -0.34 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Dare Bioscience Inc Stock (DARE) Latest News
Dare Bioscience stock maintains Buy rating at H.C. Wainwright as Bayer exits - Investing.com Canada
DARE: HC Wainwright & Co. Reiterates 'Buy' Rating with $12 Targe - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer By Investing.com - Investing.com Nigeria
Dare Bioscience (DARE) Regains Ovaprene Rights from Bayer - GuruFocus
Daré Bioscience to regain rights to hormone-free contraceptive from Bayer - Investing.com
Dare Bioscience announces return of rights to Ovaprene phase 3 program ongoing positive interim data - marketscreener.com
Dare Bioscience Announces Return Of Rights To Ovaprene Phase 3 Program Ongoing Positive Interim Data - TradingView
DAREDare Bioscience Inc Latest Stock News & Market Updates - Stock Titan
Daré Bioscience Announces Return of Rights to Ovaprene®; Phase 3 Program Ongoing; Positive Interim Data and Grant Funding Position Asset for Value-Maximization - sahmcapital.com
H.C. Wainwright Maintains Dare Bioscience(DARE.US) With Buy Rating, Maintains Target Price $12 - 富途牛牛
Daré Bioscience receives $3.6 million grant payment for contraceptive work By Investing.com - Investing.com Nigeria
DARE Secures Additional $3.6 Million from Gates Foundation - GuruFocus
Daré Bioscience Receives $3.6 Million in Additional Grant Funding - The Manila Times
Daré Bioscience receives $3.6 million grant payment for contraceptive work - Investing.com
Dare Bioscience (NASDAQ:DARE) Stock Passes Below 200-Day Moving Average – What’s Next? - Defense World
Daré targets DARE to PLAY launch in December 2025 as dual path strategy accelerates - MSN
Daré Bioscience Reports Third Quarter 2025 Financial Results and Provides Corporate Update - The Manila Times
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Str - GuruFocus
Dare Bioscience Inc (DARE) Q3 2025 Earnings Call Highlights: Strategic Advances and Financial ... - Yahoo Finance
Daré Bioscience (DARE) Q3 2025 Earnings Transcript - AOL.com
Transcript : Daré Bioscience, Inc., Q3 2025 Earnings Call, Nov 13, 2025 - MarketScreener
Earnings call transcript: Dare Bioscience Q3 2025 sees mixed stock reaction - Investing.com Nigeria
Dare Bioscience, Inc. (DARE) Reports Q3 Loss, Lags Revenue Estimates - Yahoo Finance
DARE Bioscience Prepares for Launch of Sildenafil Cream - GuruFocus
Daré Bioscience Q3 2025 Financial Results and Corporate Update - TradingView
Daré (NASDAQ: DARE) to launch DARE to PLAY Sildenafil Cream in December via 503B pathway - Stock Titan
Caribou Biosciences, Inc. (CRBU) Reports Q3 Loss, Misses Revenue Estimates - Yahoo Finance
What to Expect from Dare Bioscience's Earnings - Benzinga
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Re - GuruFocus
Earnings To Watch: Dare Bioscience Inc (DARE) Reports Q3 2025 Result - Yahoo Finance
Dare Bioscience Highlights Commercial Launch Readiness for DARE to PLAY Sildenafil Cream, November 17th Webinar to Feature Leading Clinicians Discussing Clinical Data and Potential Impact in Women's Sexual Health - MarketScreener
Multi asset correlation models including Daré Bioscience Inc.Product Launch & AI Powered Market Entry Ideas - newser.com
Dare Bioscience (DARE) to Host Webinar on Innovative Sildenafil Cream - GuruFocus
Daré Bioscience Highlights Commercial Launch Readiness for - GlobeNewswire
Daré Bioscience to Host Third Quarter 2025 Financial Results and Company Update Conference Call and Webcast on November 13, 2025 - The Manila Times
Daré Bioscience to Host Third Quarter 2025 Financial - GlobeNewswire
Daré Bioscience (NASDAQ: DARE) hosts financial results call Nov 13 at 4:30 p.m. ET - Stock Titan
Dare Bioscience (DARE) to Release Earnings on Thursday - Defense World
Daré Bioscience to Receive up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - The Manila Times
Dare Bioscience to Receive Up to $300,000 to Conduct Global Contraceptive Innovation Capabilities Landscape Assessment - MarketScreener
Daré Bioscience (NASDAQ: DARE) to receive up to $300K for global contraceptive review - Stock Titan
Will Daré Bioscience Inc. stock sustain high P E ratiosPortfolio Value Summary & Weekly Market Pulse Updates - newser.com
Daré Bioscience receives $4 million grant installment for contraceptive device By Investing.com - Investing.com Nigeria
Daré Bioscience Receives $4 Million Non-Dilutive Grant - GlobeNewswire
Law Custodial Inc. Files Schedule 13G Showing 1.41M DARE Shares - Stock Titan
Dare Bioscience (DARE) Secures $4M for Long-Acting Contraceptive Development - GuruFocus
Daré Bioscience receives $4 million grant installment for contraceptive device - Investing.com India
Daré Bioscience Receives $4 Million Non-Dilutive Grant Installment; Total of $41.8M Received to Date of up to $49M Commitment Supporting Smart Drug Delivery Device for Contraception; Platform has Broader Application Potential in Obesity and Metabolic - GlobeNewswire
$41.8M Received to Date — Daré Bioscience Advances DARE-IDDS Contraception Program, Seeks Partners - Stock Titan
Daré Bioscience enters into $15M stock purchase agreement - MSN
Dare Bioscience risks Nasdaq delisting over market value - MSN
Dare Bioscience Inc Stock (DARE) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):